The Vall d´Hebron Institute of Oncology (VHIO) Seeks a Post-Doctoral Investigator
to Join our Chromatin Dynamics in Cancer Research Group
Immediate Call for Applications
The Vall d´Hebron Institute of Oncology´s (VHIO) Chromatin Dynamics Cancer Research Group, led by Sandra Peiró, is currently seeking to appoint a Post-Doctoral Investigator. The successful candidate will form an integral part of the scientific team will support the group’s research program focused on chromatin dynamics and epigenetics in cancer.
The main goal of this laboratory is to understand the role of chromatin structure and modifications in the acquisition of malignant traits (Millanes-Romero et al; Molecular Cell 2013; Iturbide et al, Molecular Cell 2015, Pascual-Reguant, Nature Comm 2018). The successful candidate will be involved in a multidisciplinary project involving cellular and molecular biology, genome-wide data generation and bioinformatics analysis.
The appointed individual will also work on translational research projects in collaboration with oncologists to perform in vitro and in vivo drug sensitivity studies using different cancer cell lines and patient-derived xenografts (PDX) to decipher the impact of chromatin modifications and chromatin related factors in tumorigenesis and acquisition of drug resistance. He/she will also work on the optimization of functional assays using cancer patients’ biopsy samples and correlate the results with genomics data towards developing tests for patient stratification in the clinic.
An organized, motivated and team-oriented individual with prior experience working in a genomic and genome-wide research laboratory, ideally with a background in cancer research. Bioinformatics skills will be favorably considered.
We seek an individual with leadership skills, a capacity to plan, develop and execute research projects, and a purely translational, patient-centered vision of biomedical research. The successful candidate will have the necessary initiative to develop an evolving research plan according to the emergence of data and his/her personal research interests. He/she should have previous experience as a postdoctoral researcher and be able to communicate well in English, even if it is not his/her first language. Additionally, the appointed individual will be involved in the compilation of grant proposals as well as the writing of manuscripts.
Potential candidates should submit a curriculum vitae and letter of intent via email addressed to Sandra Peiró: firstname.lastname@example.org
Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
The candidate should be available to join the group ideally by January 2020, although there is some flexibility depending on the circumstances of the candidate, to be discussed at the interview.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: http://www.vhio.net.